Literature DB >> 9820345

Perforated duodenal ulcer: an alternative therapeutic plan.

A J Donovan1, T V Berne, J A Donovan.   

Abstract

An alternative plan for the treatment of a perforated duodenal ulcer is proposed. We will focus on the now-recognized role of Helicobacter pylori in the genesis of the majority of duodenal ulcers and on the high rate of success of therapy with a combination of antibiotics and a proton-pump inhibitor or histamine2 blocker in treatment of such ulcers. Knowledge that half the cases of perforated duodenal ulcer may have securely sealed spontaneously at the time of presentation is incorporated in the therapeutic plan. Patients with a perforated duodenal ulcer who have already been evaluated for H pylori and are not infected or, if infected, have received appropriate therapy should undergo an ulcer-definitive operation if they are suitable surgical candidates. Most authorities recommend surgical closure of the perforation and a parietal cell vagotomy. The remaining patients should have a gastroduodenogram with water-soluble contrast medium. If the perforation is sealed, the patient can be treated nonsurgically. If the perforation is leaking, secure surgical closure of the perforation is necessary. Following recovery from the immediate consequences of the perforation, evaluation for H pylori should be conducted. If the patient is infected, combined medical therapy is recommended. If the patient is not infected, Zollinger-Ellison syndrome should be ruled out and medical therapy is recommended if the ulcer has not been treated previously. Elective ulcer-definitive surgery should be considered for the occasional uninfected patient who has already received appropriate medical therapy for the ulcer.

Entities:  

Mesh:

Year:  1998        PMID: 9820345     DOI: 10.1001/archsurg.133.11.1166

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  20 in total

Review 1.  Rupture of the lesser gastric curvature after a Heimlich maneuver.

Authors:  A Gallardo; R Rosado; D Ramírez; P Medina; S Mezquita; J Sánchez
Journal:  Surg Endosc       Date:  2003-06-19       Impact factor: 4.584

Review 2.  Emergency ulcer surgery.

Authors:  Constance W Lee; George A Sarosi
Journal:  Surg Clin North Am       Date:  2011-10       Impact factor: 2.741

3.  Gastric perforations associated with the use of crack cocaine.

Authors:  Bani Chander; Harry R Aslanian
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-11

4.  Routine versus selective upper gastrointestinal contrast series after omental patch repair for gastric or duodenal perforation.

Authors:  Stephenie Poris; Andrew Fontaine; Julie Glener; Stacey Kubovec; Paula Veldhuis; Yuan Du; Julie Pepe; Steve Eubanks
Journal:  Surg Endosc       Date:  2017-06-29       Impact factor: 4.584

Review 5.  Perforated peptic ulcer - an update.

Authors:  Kin Tong Chung; Vishalkumar G Shelat
Journal:  World J Gastrointest Surg       Date:  2017-01-27

6.  Operations for peptic ulcer disease: paradigm lost.

Authors:  W H Schwesinger; C P Page; K R Sirinek; H V Gaskill; G Melnick; W E Strodel
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

7.  An example of the healing powers of a human being.

Authors:  Nicholas Charles Bosanko; Matthew J V Lewis; Yum S Chan; Claire L Winkles; Mark Moss
Journal:  BMJ Case Rep       Date:  2009-02-26

Review 8.  [Ulcer surgery - what remains?].

Authors:  A H Hölscher; E Bollschweiler; S P Mönig
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

9.  Gastrointestinal perforation secondary to COVID-19: Case reports and literature review.

Authors:  Reem J Al Argan; Safi G Alqatari; Abir H Al Said; Raed M Alsulaiman; Abdulsalam Noor; Lameyaa A Al Sheekh; Feda'a H Al Beladi
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

10.  Comparison of closure of gastric perforation ulcers with biodegradable lactide-glycolide-caprolactone or omental patches.

Authors:  Marietta J O E Bertleff; Toon Stegmann; Robert S B Liem; Geert Kors; Peter H Robinson; Jean Philippe Nicolai; Johan F Lange
Journal:  JSLS       Date:  2009 Oct-Dec       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.